期刊论文详细信息
LIFE SCIENCES 卷:217
Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation
Article
Shi, Zhengzheng1,2,3  Zhou, Qing1,2,3  Gao, Shuhong4  Li, Wenzhi1  Li, Xin5  Liu, Zhiming1  Jin, Pengpeng6  Jiang, Jie1 
[1] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China
[2] Key Lab Gynecol Oncol Shandong Prov, Jinan 250012, Shandong, Peoples R China
[3] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gynecol, Wenzhou 325000, Zhejiang, Peoples R China
[4] Binzhou Med Univ, Affiliated Hosp, Dept Obstet & Gynecol, Binzhou 256603, Shandong, Peoples R China
[5] Zaozhuang Municipal Hosp, Dept Gynecol, Zaozhuang 277000, Shandong, Peoples R China
[6] Fudan Univ, Pudong Med Ctr, Shanghai Pudong Hosp, Ctr Med Res & Innovat, Shanghai 201399, Peoples R China
关键词: Silibinin;    Endometrial carcinoma;    STAT3;    SREBP1;    Proliferation;    Apoptosis;    Lipid metabolism;   
DOI  :  10.1016/j.lfs.2018.11.037
来源: Elsevier
PDF
【 摘 要 】

Aims: To seek new conservative treatments for young women with early-stage endometrial carcinoma (EC) who desire to retain fertility, we investigated the effects and the underlying mechanism of silibinin in EC, which exhibits promising anti-cancer and tumour-suppressing properties in many malignant tumours. Main methods: Through relevant experiments such as MTT assay, cell colony formation assay and subcutaneous xenograft experiment, we showed that silibinin inhibited the proliferation of EC cells and tumours. Silibinin significantly induced cell cycle arrest and promoted apoptosis in vitro. In vivo TUNEL assay confirmed the apoptotic effect caused by silibinin. STAT3 is activated in the development of tumours. Silibinin notably inhibited the expression of STAT3 phosphorylation and regulated the expression of downstream genes involved in cell cycle and apoptosis at protein and mRNA levels in EC cells. Furthermore, silibinin decreased the expression of intranuclear SREBP1, which is a key regulator of lipid metabolism in the nucleus, and reduced the lipid accumulation in EC cells. Downregulation of the expression levels of SREBP1 and its downstream genes associated with lipid metabolism was also observed in silibinin-treated EC cells. Key findings: The results revealed that a novel anticancer drug, silibinin, markedly suppressed cell proliferation, cell cycle progression, apoptosis inhibition and lipid accumulation by blocking STAT3 and SERBP1 signalling pathways in EC cells.

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_lfs_2018_11_037.pdf 10102KB PDF download
  文献评价指标  
  下载次数:8次 浏览次数:2次